NCT00780494View on ClinicalTrials.gov

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Stomach CancerGastric (Stomach) CancerNeoplasm of Cardioesophageal JunctionGastrointestinal Stromal Tumor (GIST)
Interventions
DRUG

bevacizumab

Intravenous 15 mg/kg

DRUG

carboplatin

AUC 6, Intravenously Day 1 every 21 days

DRUG

capecitabine

850mg/m2, Orally twice daily days 1-14 every 21 days.

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Stanford University

OTHER

NCT00780494 - Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma | Biotech Hunter | Biotech Hunter